Pharmaceutical companies raised the list prices of at least 250 prescriptions heading into 2025 as major changes to the ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Experts propose potential workarounds for obstacles to wider use of combined clinics and personalized medicine for ...

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $56.56 which represents a slight increase of $0.50 or 0.89% from the prior close of $56.06. The stock opened at $56.07 and ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Plus: Drugmakers will raise U.S. prices on over 250 medicines starting January 1. Dry January, polar plunging and more ...

Starting New Year’s Day, drugmakers were set to increase prices on at least 250 brand-name medications, according to data ...

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025. Mr. Coiante is a ...

More than 250 medications, including Paxlovid and cancer therapies, will see price increases in the United States beginning ...